 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: The effectiveness and safety of neurokinin-1 receptor antagonist fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) in preventing nausea and vomiting caused by hyperemetic chemotherapy

J Clin Oncol: The effectiveness and safety of neurokinin-1 receptor antagonist fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) in preventing nausea and vomiting caused by hyperemetic chemotherapy

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

chemotherapy melanoma

take 2 zyrtec

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Chemotherapy-induced nausea and vomiting (CINV) are often toxicities that occur after chemotherapy for malignant tumors
.

Especially cisplatin-induced CINV mainly occurs within a few days after chemotherapy, so it often occurs after discharge from the hospital, causing serious discomfort to patients

Chemotherapy-induced nausea and vomiting (CINV) are often toxicities that occur after chemotherapy for malignant tumors

Recently, a phase III clinical study was published in the Journal of Clinical Oncology, comparing two neurokinin-1 receptor antagonists fosnetupitant (FosNTP) and fosaprepitant (FosAPR) combined with palonosetron and dexamethasone head-to-head Effectiveness and safety of preventing nausea and vomiting caused by highly emetic chemotherapy

The study is a randomized, double-blind phase III clinical study
.

The study randomly assigned patients planning to receive cisplatin chemotherapy to FosNTP 235 mg or FosAPR 150 mg combined with palonosetron 0.

The study is a randomized, double-blind phase III clinical study

The study consists of two parts, the one receiving single-agent chemotherapy is called S-cycle; and the other part receiving combined chemotherapy is M-cycles

In S-cycl, the total CR rate (primary endpoint) of the FosNTP and FosAPR groups were 75.

CR rate comparison

Analysis of CR rates in different time periods after chemotherapy found that the CR rates of delayed and exceeded delayed phases (120-168 hours) and 0-168 hours were 76.
8% vs 72.
8%, 86.
5% vs 81.
4%, and 73.
2% vs 66.
9%, respectively
.

The hazard ratio for TTF was 0.

Analysis of CR rates in different time periods after chemotherapy found that the CR rates of delayed and exceeded delayed phases (120-168 hours) and 0-168 hours were 76.

TTF comparison between the two groups

Adverse events (AEs) in the FosNTP and FosAPR groups were 99.
5% and 99.
0%, respectively; the incidence of treatment-related adverse events (TRAEs) was 22.
2% and 25.
4%, respectively; the incidence of ≥3 grade TRAEs was 2.
6% v 3.
1%, respectively
.

The incidence of adverse events related to injection site reactions or treatment-related adverse events were 11.

Adverse events (AEs) in the FosNTP and FosAPR groups were 99.

Adverse reactions

No serious TRAEs and AEs leading to death were observed in the FosNTP group
.

The severe TRAEs in the FosAPR group were ischemic colitis and erythema multiforme
.

No serious TRAEs and AEs leading to death were observed in the FosNTP group
.
The severe TRAEs in the FosAPR group were ischemic colitis and erythema multiforme
.

In summary, studies have shown that FosNTP has non-inferiority compared with FosAPR, and has good safety and lower risk of injection site reactions
.

In summary, studies have shown that FosNTP has non-inferiority compared with FosAPR, and has good safety and lower risk of injection site reactions
.
Studies have shown that FosNTP has non-inferiority compared with FosAPR, and has good safety and lower risk of injection site reactions
.
Studies have shown that FosNTP has non-inferiority compared with FosAPR, and has good safety and lower risk of injection site reactions
.

Original source:

Hata A, Okamoto I, Inui N, et al Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
J Clin Oncol.
2021 Nov 18:JCO2101315.
doi: 10.
1200/JCO.
21.
01315.
Epub ahead of print.
PMID: 34793245.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.